First half of the financial year 2024/25: Strong organic growth and margin expansion continue – strategy execution on track
Adjusted EBITDA rose to CHF 216.1 million and adjusted EBITDA margin expanded to 15.2% (+60 bps). This marks a fifth consecutive half-year with improved margins. The transformation program continued ...
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
PharmiWeb31m
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
Hosted on MSN57m
Mercedes-Benz Passenger car and Formula 1 engineers team up as solid-state battery road tests begin
Mercedes-Benz engineers from the road and racetrack and Factorial cell engineers have worked together on delivering an all-new solid-state battery test program, which has brought the first car powered ...